Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The efficacy and safety of escitalopram augmentation of risperidone and olanzapine in treatment resistant schizophrenia: a double blind placebo controlled pilot study

Next Previous
X
Search
Trial Profile

The efficacy and safety of escitalopram augmentation of risperidone and olanzapine in treatment resistant schizophrenia: a double blind placebo controlled pilot study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram; Olanzapine; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Dec 2010 Biomarkers information updated
    • 06 Dec 2010 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top